Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium

Emil Ruvinov1, Orna Sharabani-Yosef1, Arnon Nagler2, Tom Einbinder3, Micha S Feinberg1, Radka Holbova1, Amos Douvdevani3 and Jonathan Leor*1

Address: 1Neufeld Cardiac Research Institute, Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Israel, 2Institute of Hematology, Sheba Medical Center, Tel-Hashomer, Israel and 3Department of Nephrology, Soroka University Medical Center, Ben-Gurion University, Beer-Sheva, Israel

Email: Emil Ruvinov - emilr78@gmail.com; Orna Sharabani-Yosef - ornashy@yahoo.com; Arnon Nagler - a.nagler@sheba.health.gov.il; Tom Einbinder - etom@bezeqint.net; Micha S Feinberg - micha.feinberg@sheba.health.gov.il; Radka Holbova - rholbova@yahoo.co.uk; Amos Douvdevani - amosd@bgu.ac.il; Jonathan Leor* - leorj@post.tau.ac.il

* Corresponding author

Abstract

Background: Erythropoietin possesses cellular protection properties. The aim of the present study was to test the hypothesis that in situ expression of recombinant human erythropoietin (rhEPO) would improve tissue repair in rat after myocardial infarction (MI).

Methods and results: RhEPO-producing cardiac fibroblasts were generated ex vivo by transduction with retroviral vector. The anti-apoptotic effect of rhEPO-producing fibroblasts was evaluated by co-culture with rat neonatal cardiomyocytes exposed to H2O2-induced oxidative stress. Annexin V/PI assay and DAPI staining showed that compared with control, rhEPO forced expression markedly attenuated apoptosis and improved survival of cultured cardiomyocytes. To test the effect of rhEPO on the infarcted myocardium, Sprague-Dawley rats were subjected to permanent coronary artery occlusion, and rhEPO-producing fibroblasts, non-transduced fibroblasts, or saline, were injected into the scar tissue seven days after infarction. One month later, immunostaining identified rhEPO expression in the implanted engineered cells but not in controls. Compared with non-transduced fibroblasts or saline injection, implanted rhEPO-producing fibroblasts promoted vascularization in the scar, and prevented cell apoptosis. By two-dimensional echocardiography and postmortem morphometry, transplanted EPO-engineered fibroblasts did not prevent left ventricular (LV) dysfunction and adverse LV remodeling 5 and 9 weeks after MI.

Conclusion: In situ expression of rhEPO enhances vascularization and reduces cell apoptosis in the infarcted myocardium. However, local EPO therapy is insufficient for functional improvement after MI in rat.
Background
Erythropoietin (EPO), a hematopoietic cytokine, has been shown to possess cardioprotective characteristics that can minimize ischemic injury and improve myocardial viability and function [1]. Systemic administration of recombinant human EPO (rhEPO) before or after myocardial ischemia reduces infarct size and improves cardiac function [2,3]. The beneficial effects of EPO are mediated by apoptosis inhibition, driven by Akt/phosphoinositide3-kinase signaling [4,5], and neovascularization by stimulation of endothelial progenitor cells [6,7]. However, systemic administration of EPO to patients with coronary artery disease could lead to adverse effects, such as high viscosity, impaired tissue perfusion, high blood pressure and an increased incidence of thrombosis [8,9]. Hematocrit elevation has been linked to excess mortality in patients with ischemic heart disease [10,11]. Over-expression of rhEPO in transgenic mice resulted in cardiac dysfunction and reduced life span [12,13]. Overall, the potential adverse effects associated with systemic EPO administration suggest that alternative approaches are needed.

A particularly beneficial approach would be a strategy that could provide local rhEPO delivery into the infarcted heart. A recent study has suggested that cardiac fibroblasts are critical effectors for erythropoietin-mediated pro-survival signaling and cardiac protection [14]. In the present study, we aimed to test the hypothesis that cardiac fibroblasts can be reprogrammed ex vivo to produce rhEPO, and that re-implantation of the engineered cells into the infarcted myocardium could promote tissue healing and repair.

Materials and methods
The study was performed in accordance with the Animal Care and Use Committee guidelines of the Tel Aviv University, Tel Aviv, Israel, which conforms to the policies of the American Heart Association.

Retroviral vector
Amphotrophic rhEPO (pBabe-EPO) retrovirus-containing packaging cell line PT67 was used for retroviral vector production [15]. Twenty-four hour filtered (0.45 μm) culture virus-containing supernants were stored at -80°C for future experiments. The presence and titer of rhEPO-retroviral vector were assayed by infecting BALB/3T3 (ATCC number CCL-163) mouse fibroblast cell line and a CFU (colony-forming unit) number determination.

Isolation of cardiac cells
Cardiac fibroblasts and cardiomyocytes were isolated from 1–2 day old neonatal Sprague-Dawley rats (Harlan Lab, Jerusalem, Israel) as previously described [16]. We used a 30 minute pre-plating procedure to obtain cardiac fibroblasts and to reduce the number of non-myocyte cells in cardiomyocyte culture. The purity of obtained cardiac fibroblast culture was confirmed microscopically by characteristic cell morphology. Neonatal rat cardiomyocytes were used for oxidative stress studies and cardiac fibroblasts were used for transduction and transplantation studies.

Cell transduction
BALB/3T3 (ATCC number CCL-163) mouse fibroblast cell line and isolated cardiac fibroblasts were used for transduction experiments. RhEPO retrovirus-containing supernants were first incubated at room temperature with a Superfect cationic transfection reagent (Qiagen, Westburg Ltd., Be’er-Sheva, Israel) to a final concentration of 10 μg/ml for 15 minutes [17]. Finally, the viral stock was added to 70–80% confluent BALB/3T3 or cardiac fibroblast culture. After 24 h incubation at 37°C, puromycin selection was applied (2.5 μg/ml). Transduction efficiency was approximately 80%, as evaluated qualitatively by relative confluence determination (before and after puromycin selection). Twenty-four hour culture supernants were collected for EPO assessment. Supernants were stored at -20°C for future experiments.

Assessment of EPO production and activity

RhePO protein levels
The presence of rhEPO in transduced culture supernants was analyzed by a commercial ELISA kit (R&D Systems, Minneapolis, MN, USA). EPO concentration was normalized to 10^6 cells for 24 h.

RhEPO biologic activity (TF-1 cell proliferation assay)
EPO biological activity was analyzed using the EPO-sensitive human erythroleukemia cell line TF-1, in which proliferation and metabolic activity is EPO-dependent [18]. TF-1 cells were seeded in 96-well plates (1 × 10^5 cell per well in 100 μl of RPMI medium). A total of 100 μl of previously collected culture supernants, controls or standards (0.01 to 5 IU/ml rhEPO; Eprex, Beerse, Belgium) were added to each well. On day 5 of the experiment, TF-1 relative cell number was analyzed using colorimetric XTT assay kit (Biological Industries, Beth Haemek, Israel). The XTT assay is based on the ability of metabolically active (live) cells to reduce tetrazolium salt (XTT) to orange-colored compounds of formazan. EPO activity in supernants from rhEPO-transduced fibroblast culture was calculated from XTT rhEPO standard calibration curve. EPO relative biological activity was determined by EPO activity level/EPO protein level (measured by ELISA) ratio. This amount-normalized protein ratio was used for comparison of biological activity between expressed EPO (produced from transduced cells) and recombinant protein.
Oxidative stress
After 6 days in culture, isolated rat neonatal cardiomyocytes were pretreated with supernants collected from rhEPO-transduced or non-transduced (for control) cardiac fibroblasts for 24 h, after which H$_2$O$_2$ was directly added to culture medium to a 150 μM final concentration for 60 minutes, and the degree of apoptosis was tested.

Apoptosis assays
Annexin V/propidium iodide assay
Apoptosis assessment was performed using Annexin-V-FLUOS (fluorescein)/propidium iodide (PI) staining kit (Roche Diagnostics GmbH, Penzberg, Germany). The samples were prepared according to the manufacturer's instructions and were analyzed by flow cytometry. Annexin-V-positive and PI-negative cells were scored as apoptotic cells.

DAPI staining
Apoptotic morphological changes were evaluated by DAPI (4',6'-diamidino-2-phenylindole) staining. After oxidative stress induction, cells were gently washed with phosphate-buffered saline (PBS) and fixed with cold methanol for 10 minutes. The plates were washed twice with PBS and incubated for 5 minutes with 300 μM DAPI (catalogue number D-3571, Molecular Probes, Eugene, Oregon, USA) at 37°C. Finally, the cells were washed three times with PBS and examined by fluorescence microscopy. Apoptotic cells were identified by condensation and fragmentation of the nuclei, and were quantified by counting a total of 200 nuclei from each well and calculating the percentage of apoptotic nuclei.

Rat model of acute myocardial infarction
Male Sprague-Dawley rats (approximately 250 g; Harlan Lab, Jerusalem, Israel) were subjected to acute myocardial infarction (AMI) induction by permanent coronary artery occlusion, as previously described [19].

Cell transplantation
RhEPO-transduced and non-transduced fibroblast transplantations were performed 7 days after AMI. After 10 days in culture (7 days after transduction, 3 passages), cardiac fibroblasts were prepared for transplantation by trypsinization with 0.25% Trypsin-EDTA solution for 1 minute at 37°C. The rhEPO expression level in prepared cells was 7.0 ± 0.23 mIU/24 h/10⁶ cells. Following centrifugation (1,500 rpm, 10 minutes at room temperature) the cells were re-suspended in saline. The final cell density for implantation was 1 × 10⁶ cells/100 μl. Rats were anesthetized and the chest was opened under sterile conditions. The infarcted area was identified visually by the surface scar and wall motion akinesis. Rats were randomized and selected either for injection of 1 × 10⁶ rhEPO-transduced cells, 1 × 10⁶ non-transduced cells, or saline (n = 5 in each group). All injections were made into the center of the scar. After the injection, the air was expelled from the chest, and the surgical incision was sutured closed [19,20].

Echocardiography
Transthoracic echocardiography was performed on all animals before transplantation (baseline echocardiogram) and 5 and 9 weeks later (4 and 8 weeks post-transplantation, respectively). Echocardiograms were performed with a commercially available echocardiography system (Sonos 7500; Philips) equipped with 12.5 MHz phased-array transducer (Hewlett-Packard, Andover, MA, USA) as previously described [21,22]. All measurements were averaged over three consecutive cardiac cycles and were performed by an experienced technician who was blinded to the treatment group.

Hematocrit measurements
For evaluation of possible systemic effects of rhEPO produced from transplanted cells, hematocrit measurements were performed before or 1 and 4 weeks after transplantation.

Immunohistochemical analysis
Four weeks after transplantation, hearts were arrested with 15% KCl, perfused with formaldehyde 4% (15 mmHg) for 20 minutes, sectioned into 3–4 transverse slices, and parallel to the atrioventricular ring. Each slice was fixed with 10% buffered formalin, embedded in paraffin, and sectioned into 5 μm slices. Serial sections were stained with the following agents: anti-α-smooth muscle actin monoclonal antibodies (Sigma-Aldrich, Rehovot, Israel) to localize pericytes and arterioles for neovascularization evaluation; anti-active caspase-3 polyclonal antibodies (Biocare Medical, Walnut Creek, CA, USA) for apoptosis detection; anti-rhEPO monoclonal antibodies (R&D Systems, Minneapolis, MN, USA) to localize rhEPO production and distribution; lectin (Bandeirea simplicifolia agglutinin BS-1; Sigma-Aldrich, Rehovot, Israel) to localize vascular endothelium; and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) using Apoptag Peroxidase In situ Apoptosis Kit (S7101, Chemicon, Temecula, CA, USA) to assess apoptosis. The degree of neovascularization was evaluated by capillary blood vessel and arteriole counts in the infarct border zone (at least three different fields were counted). Apoptosis evaluation was made by active caspase-3 or TUNEL-positive cell counts in the infarct border zone (at least five different fields were counted). Co-staining was made with haematoxylin or methyl green for TUNEL.

Morphometric analysis
After perfusion pressure fixation (15 mmHg), slides stained with Masson’s trichrome (Dexmore, Israel) were
used to assess left ventricular (LV) remodeling by morphometric analysis, as previously described [23]. The following parameters were measured: LV maximal diameter (mm), average wall thickness (mm; averaged from three measurements of septum thickness), average scar thickness (mm; averaged from three measurements of scar thickness), relative scar thickness (average scar thickness/average wall thickness), LV muscle area (mm²; including the septum), LV cavity area (mm²), whole LV area (mm²), infarct expansion index ([LV cavity area/Whole LV area]/Relative scar thickness), epicardial scar length (mm), and endocardial scar length (mm).

**Statistical analysis**

All values are given as means ± standard error of the mean (SEM) from at least three independent experiments. RhEPO activity results were compared with Student’s t-test for unpaired data. Cardiomyocyte or general cell apoptosis results and blood vessel counts were compared by one-way ANOVA with Bonferroni post test.

In the echocardiography study, because each animal was used as its own control, changes between baseline and 4 weeks in the control and treated groups were assessed with paired t-tests. Comparisons of the changes from baseline to 5 and 9 weeks in the control and treatment groups were made with repeated-measure two-way ANOVA. The ANOVA model included control versus treatment and baseline versus 5 and 9 weeks as factors, as well as the interaction between the two factors. GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, California, USA) was used for analysis.

Comparison of morphometry parameters and hematocrit measurements among treatment groups was assessed by one-way ANOVA with Bonferroni post test. All tests were performed using GraphPad Prism Version 4.0. P < 0.05 was considered statistically significant.

**Results**

**Ex vivo retroviral gene transfer and rhEPO expression**

To test retroviral ability for stable expression of biologically active rhEPO, the initial transduction experiments were carried out using BALB/3T3 mouse fibroblast cell line. Table 1 describes the activity of EPO produced from transduced cells. ELISA was used to evaluate EPO concentrations, and its biological activity was determined by proliferation of the EPO-sensitive human erythroleukemia cell line TF-1. The activity induced by recombinant human EPO (Eprex) was used as a standard in this assay. Produced EPO protein was found to be 35 times more biologically active than recombinant protein (Eprex; Table 1, p = 0.0006). The rhEPO production level in transduced cultures was 11.5 ± 0.8 mIU/24 h/10⁶ cells.

To generate viable cardiac cell culture producing rhEPO for subsequent transplantation, we used rat neonatal cardiac fibroblasts. EPO activity parameters of transduced cardiac fibroblasts are presented in Table 1. The produced protein was found to be 12 times more active than recombinant protein (Eprex; p = 0.03). The rhEPO production level in transduced cells was 14.2 ± 3.1 mIU/24 h/10⁶ cells.

**Anti-apoptotic effect of EPO in isolated cardiomyocytes**

The rate of apoptosis was significantly lower in cultured cardiomyocytes treated with supernants derived from rhEPO-transduced fibroblasts. To determine the protective effect of rhEPO produced from genetically modified cardiac fibroblasts on cardiomyocyte apoptosis, we used an H₂O₂-induced oxidative stress model [24]. Isolated rat neonatal cardiomyocytes were treated with 150 μM H₂O₂ for 60 minutes, with or without 24 h preconditioning with supernants containing rhEPO (12 mIU/ml) from transduced cardiac fibroblasts. The degree of apoptosis was assayed by Annexin V/PI staining and morphologically evaluated using a DAPI nuclear stain. FACS analysis of Annexin V/PI staining showed that the percentage of apoptotic cells was significantly lower in cardiomyocytes pretreated with rhEPO-containing supernants compared with control (Figure 1A): 17.8 ± 2.3% versus 32.1 ± 3.7% apoptotic cells (p < 0.05).

Morphological changes in cells that were exposed to oxidative stress were evaluated after DAPI staining. Apoptotic nuclei counts showed a significant reduction in cell death in cells treated with rhEPO-containing supernants, com-

| Table 1: EPO biological activity in vitro |
|----------------------------------------|
| Culture                   | EPO ELISA (mIU/ml) | EPO activity assay (TF-1) (mIU/ml) | Activity ratio (activity/protein) |
|---------------------------|--------------------|----------------------------------|---------------------------------|
| Mock BALB/3T3             | 0                  | 0                                | -                               |
| Transduced BALB/3T3       | 10.74 ± 0.78       | 373.3 ± 37.12*                   | ×35                             |
| Mock neonatal fibroblasts | 0                  | 0                                | -                               |
| Transduced neonatal fibroblasts | 51.24 ± 11.17   | 576.7 ± 186.7*                   | ×12                             |

RhEPO protein levels: the presence of rhEPO in transduced culture supernants was analyzed by a commercial ELISA kit. RhEPO biologic activity (TF-1 cell proliferation assay): EPO biological activity was analyzed using the EPO-sensitive human erythroleukemia cell line TF-1, in which proliferation and metabolic activity is EPO-dependent. *Significantly more active than rhEPO standard (Eprex), p < 0.05.
**RhEPO inhibits H$_2$O$_2$-induced apoptosis in isolated cardiomyocytes.** Neonatal rat cardiomyocytes were treated with PBS as a control or with H$_2$O$_2$ (150 μM) for 60 minutes in the 24 h presence or absence of rhEPO produced from transduced fibroblasts (12 mIU/ml). (A) Annexin V/PI staining: (a) Representative density profile (percentage of cells in each quadrant is indicated); (b) Quantitative analysis, showing that EPO attenuated cardiomyocyte apoptosis. (B) DAPI staining: (a) representative photomicrographs (arrows show apoptotic cardiomyocyte nuclei (chromatin condensation and nuclei fragmentation); (b) quantitative analysis, as represented by relative apoptotic nuclei counts.

**Table 2: Serial hematocrit measurements in rats after MI, showing that EPO-transduced cell injection does not increase systemic hematocrit levels**

| Treatment time                | Saline (n = 9) | EPO-transduced cells (n = 9) | Non-transduced cells (n = 9) |
|--------------------------------|----------------|-----------------------------|-----------------------------|
| Baseline (before injection; %)| 47.5 ± 0.3     | 47.2 ± 0.2                  | 47.2 ± 0.1                  |
| 1 week post-injection (%)     | 47.4 ± 0.2     | 47.0 ± 0.1                  | 47.39 ± 0.2                 |
| 4 weeks post-injection (%)    | 47.4 ± 0.18    | 46.8 ± 0.2                  | 47.15 ± 0.2                 |

$p = 1.00$. 

**Figure 1**

RH EPO inhibits H$_2$O$_2$-induced apoptosis in isolated cardiomyocytes.
pared to untreated cells: $13.5 \pm 0.6\%$ versus $19.0 \pm 0.7\%$, $p < 0.001$ (Figure 1B).

**In situ expression of erythropoietin promotes cytoprotection and vascularization**

There was no difference among the groups in the levels of hematocrit at all time points (Table 2). Four weeks after cell transplantation, heart tissue sections were stained with anti-rhEPO monoclonal antibodies to detect rhEPO expression from implanted cells. Human kidney tissue was used as positive control (Figure 2A). RhEPO was detected only in hearts treated with transduced cardiac fibroblasts 5 weeks post MI (Figure 2B–D). The staining was identified in all animals treated with transduced cells ($n = 5$), towards the center of the infarct zone.

The degree of vascularization was evaluated by counting capillary blood vessels in the infarct border zones using $\alpha$-smooth muscle actin and lectin stainings for vascular endothelium localization. Compared with non-transduced fibroblasts and saline, implanted rhEPO-producing fibroblasts enhanced angiogenesis, as shown in both $\alpha$-smooth muscle actin (Figure 3A; $15.27 \pm 0.37$ versus $9.93 \pm 0.97$ versus $9.57 \pm 0.72$ vessels/mm$^2$, respectively, $p < 0.05$), and lectin stained sections (Figure 3B; $70.1 \pm 8.5$ versus $47.5 \pm 5.9$ versus $20.7 \pm 3.6$ vessels/mm$^2$, respectively, $p < 0.05$).

Apoptosis in infarcted hearts was detected by active caspase-3 staining with polyclonal antibodies detecting only the active (effector) form of caspase-3 (Figure 4A) [25,26]. Human tonsil tissue was used as a positive control (Figure 4A, a). RhEPO-transduced cell transplantation resulted in a significant decrease in the number of active-caspase-3 positive cells ($24 \pm 6$ versus $176 \pm 20$ versus $110 \pm 27$ cells per mm$^2$ in saline and non-transduced cell injections, $p < 0.05$; Figure 4C, a). The staining revealed mainly nuclear localization of active caspase-3 (Figure 4A) [26]. Apoptosis was also evaluated by commercially available TUNEL kit (Figure 4B). Rat mammary gland tissue served as a positive control (Figure 4B, a). Similar to active caspase-3 staining, TUNEL staining showed that rhEPO-transduced...
cell transplantation resulted in a significant decrease in the number of apoptotic cells (118 ± 6 versus 182 ± 12 versus 157 ± 10 cells per mm² in saline and non-transduced cell injections, p < 0.05; Figure 4C, b). These results suggest that local rhEPO expression prevented cardiac cell apoptosis in vivo.

**EPO-transduced cell injection did not improve LV remodeling and function**

To examine potential cardioprotective effects of rhEPO-producing fibroblasts in vivo, we used a rat model of AMI, which resulted in progressive LV remodeling and dysfunction [19]. Overall, 45 rats were included in the final transplantation study. Rats were randomized into three treatment groups (n = 15 in each group): transduced rhEPO-producing cells, non-transduced cells, and saline injection. Ten animals from each group (five additional animals in each group were sacrificed one month after transplantation for immunohistochemical examination) were assessed with echocardiography.

Serial echocardiography tests showed that EPO-transduced and non-transduced cell injection did not reduce LV remodeling and dysfunction 5 and 9 weeks post MI (Table 3). At 5 weeks, there was a trend towards more scar thinning in the EPO-treated group (anterior wall diastolic thickness, p = 0.07; LV end diastolic dimension, p = 0.08).

Morphometric analysis of the infarcted hearts showed that EPO-transduced cell injection also fails to prevent infarct expansion and scar thinning (Table 4). For major parameters (average scar thickness, LV cavity area, whole LV area and expansion index), EPO-transduced cells showed significant adverse remodeling compared to non-transduced cells with a magnitude similar to saline-treated animals. Furthermore, non-transduced cell injection attenuated infarct expansion and preserved LV area, compared to saline-treated animals.

**Discussion**

To the best of our knowledge, the present study is the first to use reprogrammed cardiac fibroblasts encoding the rhEPO gene to repair infarcted myocardium in situ. In previous experiments, rhEPO was delivered systemically prior to, at different time points and immediately after ischemia/reperfusion or cardiomyopathy induction [27-30]. In our study, rhEPO produced from genetically modified cardiac fibroblasts exhibited a strong anti-apoptotic effect in vitro, promoted angiogenesis and attenuated apoptosis in the infarcted tissue. However, despite positive in vitro results and cytoprotection of EPO-transduced cells in the infarcted hearts, restoration of LV function was not observed, and there was a trend to more adverse remodeling.

![Figure 4](image-url) Four weeks after cell transplantation, rhEPO expression attenuates cardiac cell apoptosis in vivo. (A) Representative photomicrographs of active caspase-3 staining (brown) in infarcted hearts (infarct border zone). Arrows show nuclear active caspase-3 staining. (a) Human tonsil tissue (positive control); (b) saline injection; (c) non-transduced cell injection; (d) rhEPO-transduced cell injection. (B) Representative photomicrographs of TUNEL staining (brown) in infarcted hearts (infarct border zone). (a) Rat mammary gland tissue (positive control); (b) saline injection; (c) non-transduced cell injection; (d) rhEPO-transduced cell injection. (C) Quantitative analysis of apoptosis in infarcted hearts. (a) active caspase-3 staining; (b) TUNEL.
Table 3: Comparison of LV remodeling and function between EPO-transduced, non-transduced cell or saline injections by two-dimensional echocardiography, before (baseline), or 5 or 9 weeks after MI

|                        | EPO-transduced cells (n = 10) | Non-transduced cells (n = 9) | Saline (n = 9) | p*  |
|------------------------|-------------------------------|-----------------------------|---------------|-----|
| **5-week follow-up**   |                               |                             |               |     |
| Heart rate             |                               |                             |               | 0.17|
| Baseline               | 308.8 ± 12.6                  | 273.8 ± 11.7                | 273.0 ± 11.6  |     |
| 5 weeks                | 252.7 ± 9.5                   | 252.5 ± 14.0                | 262.8 ± 13.5  |     |
| p*                    | 0.0068                        | 0.32                        | 0.55          |     |
| AW d (cm)              |                               |                             |               | 0.07|
| Baseline               | 0.13 ± 0.01                   | 0.17 ± 0.007                | 0.13 ± 0.01   |     |
| 5 weeks                | 0.09 ± 0.006                  | 0.10 ± 0.01                 | 0.10 ± 0.01   |     |
| p*                    | 0.006                         | 0.0002                      | 0.04          |     |
| LVEDD                  |                               |                             |               | 0.08|
| Baseline               | 0.76 ± 0.02                   | 0.72 ± 0.02                 | 0.82 ± 0.02   |     |
| 5 weeks                | 1.06 ± 0.02                   | 0.98 ± 0.03                 | 1.00 ± 0.03   |     |
| p*                    | <0.0001                       | <0.0001                     | 0.0009        |     |
| LVESD                  |                               |                             |               | 0.22|
| Baseline               | 0.60 ± 0.03                   | 0.56 ± 0.02                 | 0.64 ± 0.03   |     |
| 5 weeks                | 0.88 ± 0.03                   | 0.81 ± 0.04                 | 0.80 ± 0.04   |     |
| p*                    | <0.0001                       | <0.0001                     | 0.0011        |     |
| LVEDA                  |                               |                             |               | 0.34|
| Baseline               | 0.39 ± 0.03                   | 0.35 ± 0.01                 | 0.43 ± 0.02   |     |
| 5 weeks                | 0.73 ± 0.04                   | 0.65 ± 0.04                 | 0.67 ± 0.05   |     |
| p*                    | <0.0001                       | <0.0001                     | 0.0011        |     |
| LVESA                  |                               |                             |               | 0.36|
| Baseline               | 0.24 ± 0.02                   | 0.21 ± 0.01                 | 0.26 ± 0.02   |     |
| 5 weeks                | 0.52 ± 0.04                   | 0.42 ± 0.04                 | 0.44 ± 0.05   |     |
| p*                    | <0.0001                       | <0.0001                     | 0.0004        |     |
| FS (%)                 |                               |                             |               | 0.99|
| Baseline               | 20.6 ± 2.9                    | 22.3 ± 1.7                  | 25.07 ± 2.2   |     |
| 5 weeks                | 16.2 ± 1.4                    | 17.8 ± 1.6                  | 20.96 ± 2.0   |     |
| p*                    | 0.14                          | 0.008                       | 0.002         |     |
| **9-week follow-up**   |                               |                             |               |     |
| Heart rate             |                               |                             |               | 0.28|
| Baseline               | 303.2 ± 12.7                  | 274.4 ± 13.3                | 273.0 ± 11.6  |     |
| 9 weeks                | 242.0 ± 6.3                   | 235.5 ± 12.2                | 246.2 ± 7.7   |     |
| p*                    | 0.04                          | 0.12                        | 0.0014        |     |
| AW d (cm)              |                               |                             |               | 0.19|
| Baseline               | 0.13 ± 0.01                   | 0.17 ± 0.007                | 0.13 ± 0.01   |     |
| 9 weeks                | 0.09 ± 0.01                   | 0.12 ± 0.01                 | 0.11 ± 0.01   |     |
| p*                    | 0.03                          | 0.0002                      | 0.3           |     |
| LVEDD                  |                               |                             |               | 0.22|
| Baseline               | 0.76 ± 0.02                   | 0.72 ± 0.02                 | 0.82 ± 0.02   |     |
| 9 weeks                | 1.11 ± 0.04                   | 1.03 ± 0.03                 | 1.05 ± 0.03   |     |
| p*                    | <0.0001                       | <0.0001                     | 0.0003        |     |
| LVESD                  |                               |                             |               | 0.3 |
| Baseline               | 0.60 ± 0.03                   | 0.56 ± 0.02                 | 0.64 ± 0.03   |     |
| 9 weeks                | 0.95 ± 0.05                   | 0.84 ± 0.04                 | 0.86 ± 0.05   |     |
| p*                    | <0.0001                       | <0.0001                     | <0.0001       |     |
| LVEDA                  |                               |                             |               | 0.42|
| Baseline               | 0.39 ± 0.03                   | 0.35 ± 0.01                 | 0.43 ± 0.02   |     |
Cardiac fibroblasts present an attractive gene carrier into the infarcted heart. Although not an ‘ideal’ source for transplantation (due to lack of contractility and so on), fibroblasts, constituting the major cell population of the myocardium, can be easily obtained from clinically accessible sites, expanded in vitro without significant limitation, and, unlike cardiomyocytes, can be transduced highly efficiently by retroviral EPO-based gene transfer.

Our findings concur with other studies that show a lack of functional improvement following EPO treatment despite positive cellular effects (apoptosis inhibition and angio-

### Table 3: Comparison of LV remodeling and function between EPO-transduced, non-transduced cell or saline injections by two-dimensional echocardiography, before (baseline), or 5 or 9 weeks after MI (Continued)

|                     | EPO-transduced cells (n = 10) | Non-transduced cells (n = 9) | Saline (n = 9) | p* ANOVA |
|---------------------|-------------------------------|-----------------------------|---------------|----------|
| LVESVD (mm)         | 3.1 ± 0.2                     | 3.0 ± 0.1                   | 2.6 ± 0.1     | 0.0001   |
| p                  | <0.001†                      | <0.001†                     | -             |          |
| LVESD (mm)          | 3.0 ± 0.2                     | 2.9 ± 0.1                   | 2.4 ± 0.1     | 0.001    |
| p                  | <0.001†                      | <0.001†                     | -             |          |
| LVESA (mm²)         | 17.0 ± 3.4                    | 17.0 ± 3.4                  | 12.0 ± 3.4    | 0.003    |
| p                  | -                            | -                           | -             |          |
| Thickness (mm²)     | 1.1 ± 0.2                     | 1.1 ± 0.2                   | 1.0 ± 0.2     | 0.42     |
| p                  | -                            | -                           | -             |          |
| Expansion index     | 1.1 ± 0.08                    | 1.0 ± 0.05                  | 1.2 ± 0.13    | 0.03     |
| p                  | -                            | <0.05†                      | -             |          |
| Epicardial scar length (mm) | 7.2 ± 1.2                   | 6.4 ± 1.2                   | 7.3 ± 1.6     | 0.02     |
| p                  | -                            | -                           | -             |          |
| Endocardial scar length (mm) | 7.3 ± 1.6                   | 6.2 ± 1.2                   | 6.6 ± 1.0     | 0.05     |
| p                  | -                            | -                           | -             |          |

Values are means ± SEM. p (Bonferroni test), p-values from Bonferroni multiple comparison test; p*, p-values for the differences between groups (one-way ANOVA). †Versus non-transduced cells; ‡versus saline; §versus saline and non-transduced cells.

### Table 4: Comparison of LV remodeling by postmortem morphometry, 9 weeks after MI

|                     | EPO-transduced cells (n = 10) | Non-transduced cells (n = 9) | Saline (n = 9) | p* ANOVA |
|---------------------|-------------------------------|-----------------------------|---------------|----------|
| LV maximal diameter (mm) | 8.2 ± 0.4                     | 6.2 ± 0.31                  | 8.1 ± 0.33    | <0.0001  |
| p (Bonferroni test)     | <0.001†                      | <0.001†                     | -             |          |
| Average wall thickness (mm) | 1.4 ± 0.05                    | 1.2 ± 0.04                  | 1.4 ± 0.03    | 0.003    |
| p (Bonferroni test)     | <0.05†                      | <0.05†                     | -             |          |
| Average scar thickness (mm) | 0.62 ± 0.03                  | 0.92 ± 0.04                 | 1.0 ± 0.05    | <0.0001  |
| p (Bonferroni test)     | <0.001†                      | -                           | -             |          |
| Relative scar thickness | 0.46 ± 0.05                   | 0.59 ± 0.03                 | 0.56 ± 0.05   | 0.22     |
| p (Bonferroni test)     | -                            | -                           | -             |          |
| Muscle area (mm²)      | 43 ± 1.4                      | 43 ± 4.2                    | 47 ± 2.3      | 0.55     |
| p (Bonferroni test)     | -                            | -                           | -             |          |
| LV cavity area (mm²)   | 57 ± 8.0                      | 40 ± 4.9                    | 65 ± 5.3      | 0.002    |
| p (Bonferroni test)     | <0.05†                      | <0.01†                     | -             |          |
| Whole LV area (mm²)    | 110 ± 7.5                     | 77 ± 7.0                    | 110 ± 7.0     | <0.0001  |
| p (Bonferroni test)     | <0.001†                      | < 0.001†                   | -             |          |
| Expansion index        | 1.1 ± 0.08                    | 0.89 ± 0.05                 | 1.2 ± 0.13    | 0.04     |
| p (Bonferroni test)     | -                            | <0.05†                     | -             |          |
| Epicardial scar length (mm) | 7.2 ± 1.2                   | 6.5 ± 1.2                   | 8.1 ± 1.6     | 0.68     |
| p (Bonferroni test)     | -                            | -                           | -             |          |
| Endocardial scar length (mm) | 7.3 ± 1.6                   | 6.2 ± 1.2                   | 6.6 ± 1.0     | 0.65     |
| p (Bonferroni test)     | -                            | -                           | -             |          |
genosis) [31-35], as well as one clinical trial conducted with EPO analogue darbepoetin alfa [36].

The reason for the inconsistency between the cytoprotective effect of EPO in vitro and in situ versus the lack of functional improvement in vivo is unclear. A possible explanation is that an EPO therapeutic effect on LV remodeling and function is mainly mediated by endothelial progenitor cell recruitment, which is achieved by systemic administration [34,37,38]. This notion is supported by the positive correlation found between EPO plasma levels and endothelial progenitor cell recruitment in an observational study of patients after acute MI [39]. Thus, local EPO therapy is insufficient for functional improvement.

In addition, the lack of improvement could be related to the timing of therapy. In most of the positive EPO studies systemic cytokine administration was initiated before or immediately after ischemia/reperfusion induction. We used a more severely injured model with more clinically relevant timing of cell delivery (1 week post MI). However, at this stage, EPO could be less effective due to a relatively low cell apoptotic rate and the lack of stem cell homing signals from the infarct [35].

**Study limitations**

Cell engraftment and survival was not quantified. Bromodeoxyuridine (BrdU) or other cellular markers were not used to avoid interference with cell capacity to colonize and proliferate. Such interference could cause a decrease in the proposed EPO effect.

Retrovirial transduction itself can potentially alter the phenotype of the transduced cells. However, the expression profile of transduced cells did not exhibit any negative effects when the transduced cell culture supernants were added to cardiomyocyte culture in vitro.

In order to avoid possible systemic interference, we did not apply an immunosuppression protocol. However, EPO detection 1 month after cell transplantation suggests that immune response, if evoked, is limited in magnitude. The EPO tissue level could not be quantified due to technical constraints for detection of predicted low levels of the protein.

**Conclusion**

*In situ* expression of rhEPO by genetically engineered cardiac fibroblasts exerts cytoprotective and pro-angiogenic effects. However, these favorable effects were not translated into functional improvement after MI. The results suggest that for successful local EPO-based therapy, several improvements should be made to determine the optimal cell type for gene delivery, the most effective recombinant viral vector, myocardial EPO response and, notably, an accurate therapeutic window for cell and gene transfer.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

ER carried out the *in vitro* and *in vivo* experiments, including data acquisition and analysis. OS participated in study design and coordination, and helped in drafting the manuscript. AN participated in conceptual study design and coordination, and helped to draft the manuscript. TE provided help in study design, data acquisition and analysis. MF participated in data acquisition and analysis. RH carried out the *in vivo* experiments. AD participated in conceptual study design and coordination, and helped to draft the manuscript. JL conceived the study, participated in its design and coordination, and helped to draft the manuscript.

**References**

1. Maires K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. JAMA 2005, 293:90-95.

2. Parsa C, Matsumoto A, Kim J, Riel RU, Pascall LS, Walton GB, Thompson RB, Petrofsky JA, Annex BH, Stampler JS, Kotler DP: A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003, 112:999-1007.

3. Calviello L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003, 100:4802-4806.

4. Tramontano AF, Munizappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutala MV, Esher N: Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003, 308:990-994.

5. Cai Z, Semenza GL: Phosphatidylinositol-3 kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 2004, 109:2050-2053.

6. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M: Erythropoietin is a potent angiogenic factor. Eur J Clin Invest 2003, 33:891-896.

7. Heeschen C, Alcher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildeiner-Rihm C, Martin H, Zeiher A, Dimmeler S: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102:1340-1346.

8. Rao SV, Stampler JS: Erythropoietin, anemia, and orthostatic hypotension: the evidence mounts. Clin Auton Res 2002, 12:141-143.

9. Lipsic E, Schoemaker RG, Meer P, Voors AA, vanHelder P, Vandewylen V, vanGilst WH: Protective effects of erythropoietin in cardiac ischemia. From bench to bedside. J Am Coll Cardiol 2006, 48:2161-2167.

10. Besarab A, Bolton WK, Brown KE, Egie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.

11. Hebert PC, Wells G, Blachman MA, Marshall M, Martin M, Pagliarello G, Tweeddale M, Schweitzer I, Yetishir E: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999, 340:409-417.

12. Briest W, Honigk L, Babi HA, Daxen A, Rabielle B, Mannapfel A, Wagner KF, Wengen RH, Zimmer H: Cardiac remodeling in erythropoietin-transgenic mice. Cell Physiol Biochem 2004, 14:277-284.
myocardial infarction in the rat. J Cardiovasc Pharmacol 2005, 46:211-215.

32. Olea RD, Janavel GV, DeLorenzi A, Cuniberti L, Vannarelli G, Meckert PC, Cerrass M, Lagrues R, Crotogini A: High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J Cardiovasc Pharmacol 2006, 47:736-741.

33. Kristensen M, Maeng M, Rehling M, Berg JS, Mortensen UM, Nielsen SS, Nielsen TT: Lack of acute cardioprotective effect from preischaemic erythropoietin administration in a porcine coronary occlusion model. Clin Physiol Funct Imaging 2005, 25:305-310.

34. Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, Hajar R: Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007, 292:H522-529.

35. Channeuse S, Azarnoush K, Maurel A, Bellamy V, Peyrard S, Bruneval P, Hagege AA, Menasche P: Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium? Interact Cardiovasc Thorac Surg 2007, 6:293-297.

36. Lipsic E, Meer P van der, Voors AA, Westenbrink BD, de Boer HC, van Zonneveld AJ, Schoemaker RG, van Gilst WH, Zijlstra F, van Veldhuisen DJ: A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drug Ther 2006, 20:135-141.

37. Jorgensen E, Bindslv L, Ripsa RS, Kastrup J: Epo 'cytokine-doping' of heart disease patients, will it work? Eur Heart J 2006, 27:1671-1678.

38. Westenbrink BD, Lipsic E, Meer P van der, Harst P van der, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG: Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007, 28:2018-2027.

39. Ferrario M, Massa M, Rosti V, Campanelli R, Ferlini M, Marinoni B, De Ferrari GM, Meli V, De Amici M, Repetto A, Verri A, Bramucci E, Tavazzi L: Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur Heart J 2007, 28:1805-1813.

Page 11 of 11

Publish with BioMed Central and every scientist can read your work free of charge

*BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime.*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp